Navigation Links
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
Date:10/25/2007

Submission Seeks Approval of Genasense in Relapsed/Refractory Patients

BERKELEY HEIGHTS, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Company has completed the filing of the Company's formal appeal to Dr. Janet Woodcock, Acting Director of the Center for Drug Evaluation Research (CDER), at the U.S. Food and Drug Administration (FDA). The appeal asks that CDER approve the use of Genasense(R) (oblimersen sodium) Injection plus chemotherapy for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In December 2006, FDA issued a non-approvable letter for the Company's New Drug Application (NDA) for Genasense in CLL. This appeal has been submitted in accordance with the Formal Dispute Resolution process that exists within CDER. Responses to CDER appeals are typically made within 30 to 60 days.

The appeal reflects several considerations, including but not limited to the following:

- Complete responses -- the primary endpoint of the trial - were more

than doubled in the Genasense group compared with controls who received

chemotherapy alone. The difference was statistically significant.

- Complete response confers clinical benefit in CLL. By definition, a

complete response requires elimination of all evidence of disease,

normalization of blood counts, and resolution of symptoms.

- The median duration of complete response in patients who received

Genasense has exceeded 3 years, at least 50% longer compared with

controls, which is clinically meaningful and statistically significant.

Survival information from this study will be updated at the annual

meeting of the Ameri
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 Cutting-edge biotech ... food nutrition products reveal technological advancements are in ... such as hyperglycemia, obesity, insulin level issues and ... Biotech Companies in focus today are: RiceBran Technologies (NASDAQ: ... (NYSE: ANFI ), CEL-SCI Corporation (NYSE: ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... Outside GC, the leading provider of on-demand, in-house ... Casey as a member of the firm, further strengthening ... , Debbie has spent over 20 years in the ... North America in both legal and business capacities. ... Outside GC’s growing list of healthcare clients, with a ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
Breaking Biology Technology:Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 3Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 4Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 5Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 6Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 7VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Outside GC Expands Healthcare Team 2Immunovaccine Disclaims Hoax Press Release 2
... Inc. (NYSE Amex: PTN ) today announced ... a strategic reassessment of its research and development activities ... resources and efforts on clinical trials of bremelanotide for ... severe asthma. In implementing this plan, Palatin is reducing ...
... DIEGO, Sept. 24 Cylene Pharmaceuticals, Inc. announced ... trial of their first-in-class, oral CK2 inhibitor CX-4945 ... the simultaneous closing of a $12 million financing ... HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures ...
... PHILADELPHIA, BOONTON, N.J. and BRUSSELS, Sept. 24 ... Bulletin Board: UGNE ) today reported ... effects in combination with other drugs in reducing ... are being presented at the 2010 Osteoarthritis Research ...
Cached Biology Technology:Palatin Announces Strategic Realignment of Operations 2Palatin Announces Strategic Realignment of Operations 3Palatin Announces Strategic Realignment of Operations 4Palatin Announces Strategic Realignment of Operations 5Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 2Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 3Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 4Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 5
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... Israel The Israeli Chairmanship of EUREKA, the largest pan-European ... new data from a report conducted by Kalman Gayer ... Ltd., to mark the completion of Israel,s Chairmanship year ... proven impact of EUREKA on companies participating in EUREKA ...
... This release is available in German . ... congenital deaf-blindness in humans and affects 1 in 6,000 of ... both clinically and genetically heterogeneous. In the most severe cases, ... degeneration of the retina in puberty, ultimately resulting in complete ...
... are the most abundant parasites on Earth. Well known viruses, ... such as the tobacco mosaic virus infect plant hosts. ... bacteria known as bacteriophages, or phages. In part, this is ... have been cut off from their usual biological surroundings in ...
Cached Biology News:Is governmental investment in industrial R&D paying off? 2Is governmental investment in industrial R&D paying off? 3Treatment approach to human Usher syndrome: Small molecules ignore stop signals 2Treatment approach to human Usher syndrome: Small molecules ignore stop signals 3When viruses infect bacteria 2
...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
96 Well Base Plate...
Biology Products: